Monte Rosa Therapeutics, Inc. Common Stock

$15.89
USD
Last updated on --.
24h volume1.03M
24h highest16.1200 USD
24h lowest15.6500 USD
24h Price movement+1.18%

GLUE recent prices

24 Hours
+1.18%+$0.185
30 days
-34.62%-$8.330
60 days
-7.47%-$1.270
90 days
-19.49%-$3.780

Key data

Previous close15.7100 USD
Market cap1.33B USD
Volume1.03M
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)-1.5400 USD
Net income (FY)-130.01M USD
Revenue (FY)42.95M USD
Last report dateMay 7, 2026

About Monte Rosa Therapeutics, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
HeadquartersBOSTON
Employees (FY)161.00
Revenue per employee (FY)266.79K USD
Net income per employee (FY)-807.54K USD
Listed onNasdaq
Official website

GLUE conversion tables

GLUEGLUE
USDUSD
0.5 GLUE7.947 USD
1 GLUE15.89 USD
5 GLUE79.47 USD
10 GLUE158.95 USD
USDUSD
GLUEGLUE
0.5 USD0.031456 GLUE
1 USD0.062913 GLUE
5 USD0.31456 GLUE
10 USD0.62913 GLUE

FAQ

GLUE is trading at $15.89, +1.18% over the last 24 hours. Track live moves on the price chart at the top of this page.
The GLUE stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. GLUE is currently trading at $15.89, +1.18% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on GLUE price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. GLUE's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from GLUE; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against GLUE's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Monte Rosa Therapeutics, Inc. Common Stock's market cap is currently 1.33B USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume1.03M
24h highest16.1200 USD
24h lowest15.6500 USD
24h Price movement+1.18%
GLUEGLUE
USDUSD
Start trade with GLUE Perpetual